DavidPKelsenMD

Professor of Medicine, Cornell University-Weill Medical College

Overview of Dr. Kelsen

Dr. David Kelsen is an oncologist in New York, NY and is affiliated with multiple hospitals in the area, including Memorial Sloan-Kettering Cancer Center and Memorial Sloan Kettering Bergen. He received his medical degree from Drexel University College of Medicine/Hahnemann University and has been in practice 50 years. He is experienced in cholangiocarcinoma, gastrointestinal oncology, general medical oncology, and endocrine oncology. He has more than 100 publications and over 500 citings.

Office
160 East 53rd Street
New York, NY 10022
Book by Phone+1(561) 537-3494

Education & Training

Memorial Sloan Kettering Cancer CenterFellowship, Hematology and Medical Oncology, 1976 - 1978
Temple University HospitalResidency, Internal Medicine, 1972 - 1976
Drexel University College of MedicineClass of 1972

Certifications & Licensure

FL State Medical License 2022 - Present
NJ State Medical License 2019 - 2025
NY State Medical License 1976 - 2025
PA State Medical License 1973 - 1990
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

America's Top Doctors Castle Connolly, 2003-2014
Top Doctors: New York Metro Area Castle Connolly, 2002-2014
New York Magazine: Top Doctors Castle Connolly, 2002-2009, 2011-2014
America's Top Doctors for Cancer Castle Connolly, 2005-2013
Join now to see all

Clinical Trials

Combination Chemotherapy and Radiation Therapy in Treating Patients With Cancer of the Esophagus Start of enrollment: 1995 Oct 01
Completed
Phase 1
Combination Chemotherapy Before and After Surgery in Treating Patients With Stomach Cancer Start of enrollment: 1996 May 01
Completed
Phase 2
Paclitaxel in Treating Patients With Metastatic, Recurrent, or Unresectable Cancer of the Esophagus Start of enrollment: 1997 Sep 01
Unknown status
Phase 2
Gemcitabine Plus Radiation Therapy in Treating Patients With Pancreatic Cancer Start of enrollment: 1998 Apr 01
Completed
Phase 1
Combination Chemotherapy Followed by Surgery and Intraperitoneal Chemotherapy in Treating Patients With Locally Advanced Stomach Cancer Start of enrollment: 2000 Feb 01
Completed
Phase 2
Chemotherapy and Radiation Therapy With or Without Fluorouracil in Treating Patients With Cancer of the Stomach Who Have Undergone Surgery Start of enrollment: 2001 May 01
Completed
Phase 2
Study of Modified Docetaxel, Cisplatin, and Fluorouracil (mDCF) in Unresectable or Metastatic Gastric and Gastroesophageal Junction Adenocarcinoma Start of enrollment: 2006 Oct 23
Completed
Phase 2
Early Onset and Familial Gastric Cancer Registry Start of enrollment: 2005 Dec 01
Active, not recruiting
A Registry for BRCA Mutation Carriers With Pancreatic Ductal Adenocarcinoma Start of enrollment: 2013 Nov 04
Recruiting
Join now to see all

Publications & Presentations

PubMed

Assessment of the Feasibility of Hyperpolarized [1-C]pyruvate Whole-Abdomen MRI using DO Solvation in Humans.
Guannan Zhang, Kofi Deh, Hijin Park, Charles H Cunningham, Nadia D Bragagnolo
Journal of Magnetic Resonance Imaging. 2024-12-01
1 citations
Lynch Syndrome and Somatic Mismatch Repair Variants in Pancreas Cancer.
Catherine A O'Connor, Emily Harrold, David Lin, Henry Walch, Andrea Gazzo
JAMA Oncology. 2024-11-01
Adjuvant Modified FOLFIRINOX for Resected Pancreatic Adenocarcinoma (PDAC): Clinical Insights and Genomic Features from a Large Contemporary Cohort.
Fergus Keane, Catherine O'Connor, Drew Moss, Joanne F Chou, Maria A Perry
Journal of the National Cancer Institute. 2024-10-26

Authored Content

Phase II Trial of Veliparib in Patients with Previously Treated BRCA-Mutated Pancreas Ductal Adenocarcinoma☆January 2018

Press Mentions

Stress Response Protein Links Inflammatory Disease to Colon CancerFebruary 19th, 2021
Novo Nordisk's Drug for Obesity Treatment Gets FDA Panel ApprovalSeptember 12th, 2014
U.S. FDA Panel: Novo Nordisk's Liraglutide Safe, Effective for ObesitySeptember 11th, 2014

Grant Support

Early Therapeutics Development With Phase II EmphasisNational Cancer Institute2011
Early Therapeutics Development With Phase II EmphasisNational Cancer Institute2010
Tas:: 75 0850 ::Tas Recovery ACT - Actnow Clinical Trial 8461Division Of Cancer Treatment2009
Early Therapeutics Development With Phase II EmphasisDivision Of Cancer Treatment2009
Phase II/III Clinical Trials Of Anticancer AgentsNational Cancer Institute1995–2000
Neoadjuvant Therapy And Bio-Correlates Of Gastric CancerNational Cancer Institute1996–1998
Pain Relief In Pancreas CancerNational Cancer Institute1993–1995
Multimodality Treatment &Clinical-Biological CorrelatesNational Cancer Institute1992–1993
Multimodality Treatment &Clinical-Biological CorrelatesNational Cancer Institute1991
Pain Assessment In Patients With Pancreas CancerNational Cancer Institute1989–1991
Mskcc CCOP Research Base OperationsNational Cancer Institute1987–1990
C C O P Research Base OperationsNational Cancer Institute1985–1986

Insurance Accepted

Aetna Choice POS II
Aetna HMO
BCBS Blue Card PPO
BCBS Illinois PPO
BCBS Kansas City Preferred-Care Blue PPO
CIGNA HMO
CIGNA Open Access
CIGNA PPO
Empire BCBS HMO
Empire BCBS PPO
GHI PPO
Great West PPO
Humana ChoiceCare Network PPO
Multiplan PHCS PPO
Multiplan PPO
MVP Healthcare PPO
Oxford Health Freedom
Oxford Health Liberty
QualCare HMO
QualCare PPO
United Healthcare - Direct Choice Plus POS
United Healthcare - Direct Options PPO
Please verify your coverage with the provider's office directly when scheduling an appointment